Corsalex’s mission is to identify, fund, and develop promising projects to treat C9orf72 ALS/FTD.
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating adult-onset neurodegenerative diseases. Genetic analysis has revealed the hexanucleotide repeat expansion (HRE) disorder C9orf72 as the most common cause of familial ALS/FTD (C9-ALS/FTD).
Corsalex is a joint venture between KCK and Panorama Research. Led by Dr. James Larrick, a biomedical entrepreneur with an international reputation and over 30-year career in biotechnology, and backed by KCK, the Company hopes to spur innovation and advance meaningful interventions for this devastating disease.
Company Details
- Employees
- 4
- Address
- Cupertino, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.corsalex.com
- Keywords
- Cold Spring Harbor.
- HQ
- Cupertino, CA
Corsalex, Inc. Questions
Corsalex, Inc.'s website is http://www.corsalex.com
Corsalex, Inc.'s LinkedIn profile is https://www.linkedin.com/company/corsalex-inc
Corsalex, Inc. has
4 employees.
View email and phone details for 4
employees at Corsalex, Inc..
Corsalex, Inc.'s industry is
Biotechnology Research
Corsalex, Inc.'s top competitors are
Fossiliontech,
Cshl Meetings & Courses,
Sarafan Chem-H | Stanford University,
Verge Genomics,
Yale Pathology,
Panorama Research,
Amygo Solutions,
X-37,
Biospace,
Silverride.
Corsalex, Inc.'s categories are Biotechnology Research
